Pulmonary Hypertension

Triple therapy safe, effective in cystic fibrosis with single Phe508del allele - Healio Triple therapy safe, effective in cystic fibrosis with single Phe508del allele - Healio Posted: 31 Oct 2019 01:21 PM PDT Combination therapy with elexacaftor/tezacaftor/ivacaftor improved lung function and the rate of pulmonary exacerbations with minimal adverse effects in patients aged 12 years and older with cystic fibrosis with Phe508del-minimal function genotypes who did not previously respond to cystic fibrosis transmembrane conductance regulator modulator therapy, according to a study published in The New England Journal of Medicine . In the phase 3, double-blind, randomized, placebo-controlled trial, the percentage of predicted FEV 1 was 13.8 points higher among patients treated with elexacaftor/tezacaftor/ivacaftor (Trikafta, Vertex Pharmaceuticals), as compared with placebo, at 4 weeks ( P < .001) and 14.3 points higher at 24 weeks ( P ...

Beware Long-Term Effects Of Kyphoscoliosis - MedPage Today Beware Long-Term Effects Of Kyphoscoliosis - MedPage Today Posted: 21 Oct 2019 12:00 AM PDT A 61-year-old Caucasian female is admitted to the hospital in September 2018 with shortness of breath on exertion and increased fatigue during daily activities. Her symptoms, once mild, have been worsening for several years, she explains. Medical History The patient has severe congenital kyphoscoliosis of the thoracic spine (Figure). Attempted surgical correction when she was 10 years of age was not successful. She is New York Heart Association (NYHA) functional class IV, but has never smoked and has no history of prior drug abuse. She explains that she first noticed becoming short of breath in mid-2015. In June 2016, to rule out a cardiac etiology, clinicians perform a transthoracic echocardiography (TTE). This identifies signs of right ventricular overload with an elevated right vent...

Global Persistent Pulmonary Hypertension of the Newborn Pipeline Insight Report 2019 - ResearchAndMarkets.com - Business Wire Global Persistent Pulmonary Hypertension of the Newborn Pipeline Insight Report 2019 - ResearchAndMarkets.com - Business Wire Posted: 18 Oct 2019 04:32 AM PDT DUBLIN--( BUSINESS WIRE )--The "Persistent Pulmonary Hypertension of the Newborn Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering. Persistent Pulmonary Hypertension of the Newborn Pipeline Insight, 2019 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Persistent Pulmonary Hypertension of the Newborn pipeline landscape is provided which includes the disease overview and Persistent Pulmonary Hypertension of the Newborn treatment guidelines. The assessment part of the report embraces, in depth Persistent Pulmonary Hyperten...

Tenax Therapeutics Provides Update on Phase 2 Pulmonary Hypertension Clinical Trial - Business Wire Tenax Therapeutics Provides Update on Phase 2 Pulmonary Hypertension Clinical Trial - Business Wire Posted: 31 Oct 2019 05:00 AM PDT MORRISVILLE, N.C.--( BUSINESS WIRE )--Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today provided an update on its on-going clinical trial of levosimendan. Enrollment Update Tenax is conducting a multi-center, double-blind placebo controlled Phase 2 trial designed to evaluate levosimendan in patients with pulmonary hypertension and heart failure with preserved ejection fraction (PH-HFpEF). The study is also known as the HELP Trial (Hemodynamic Evaluation of Levosimendan in Patients with PH-HFpEF). The Company has activated all of it...

Miracle on Wheels - northernexpress.com Miracle on Wheels - northernexpress.com Posted: 26 Oct 2019 07:06 AM PDT Meet the 30-year-old about to test her newly transplanted heart and lungs at the 2019 Iceman Cometh race. By Al Parker | Oct. 26, 2019 Camille Frede (pictured above, center) was only 4 years old when her parents, Nancy and Eric Frede, received the devastating news that their daughter would be lucky to live to age 9. Diagnosed with pulmonary hypertension (PH), young Camille constantly struggled with health problems. She was in and out of hospitals for years. Now, 26 years later, the Grand Rapids native is living with a new heart and lungs and, on Nov. 2, will ride in the 2019 Bell's Iceman Cometh Challenge mountain bike race from Kalkaska to Traverse City. She won't tackle the 30-mile point-to-point race alone. She'll ride with family members; her doctor, Aaron Waxman; and her exercise physiologist, Julie Trace...

PH Doubles Risk of Death in People with Tricuspid Regurgitation, Study Reports - Pulmonary Hypertension News PH Doubles Risk of Death in People with Tricuspid Regurgitation, Study Reports - Pulmonary Hypertension News Posted: 11 Oct 2019 12:00 AM PDT Pulmonary hypertension contributes to markedly poorer outcomes and doubles a risk of death in people with moderate-to-severe problems in the heart's tricuspid valve, a condition known as tricuspid regurgitation, a study from Europe reports. The study, " Impact of pulmonary hypertension on outcome in patients with moderate or severe tricuspid regurgitation ," was published in the journal Open Heart . The heart has four main valves that separate the atria, ventricles, and arteries, and regulate the blood flow inside the heart. Malfunctioning valves can have a severe impact on the ability of the heart to efficiently pump the blood to the lungs and th...

Tenax Therapeutics Provides Update on Phase 2 Pulmonary Hypertension Clinical Trial - Business Wire Tenax Therapeutics Provides Update on Phase 2 Pulmonary Hypertension Clinical Trial - Business Wire Posted: 31 Oct 2019 05:00 AM PDT MORRISVILLE, N.C.--( BUSINESS WIRE )--Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today provided an update on its on-going clinical trial of levosimendan. Enrollment Update Tenax is conducting a multi-center, double-blind placebo controlled Phase 2 trial designed to evaluate levosimendan in patients with pulmonary hypertension and heart failure with preserved ejection fraction (PH-HFpEF). The study is also known as the HELP Trial (Hemodynamic Evaluation of Levosimendan in Patients with PH-HFpEF). The Company has activated all of it...